BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $83.00 at Oppenheimer

BridgeBio Pharma (NASDAQ:BBIO) had its price objective boosted by Oppenheimer from $81.00 to $83.00 in a report issued on Friday morning,Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

A number of other research analysts have also recently commented on BBIO. Wells Fargo & Company increased their price target on shares of BridgeBio Pharma from $88.00 to $98.00 and gave the company an “overweight” rating in a research report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BridgeBio Pharma in a report on Wednesday, January 21st. Raymond James Financial set a $89.00 target price on shares of BridgeBio Pharma and gave the stock an “outperform” rating in a research report on Thursday. Sanford C. Bernstein assumed coverage on shares of BridgeBio Pharma in a research report on Thursday, December 11th. They set an “outperform” rating and a $94.00 price target for the company. Finally, TD Cowen reaffirmed a “buy” rating on shares of BridgeBio Pharma in a research note on Monday, January 12th. Twenty-two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, BridgeBio Pharma has an average rating of “Moderate Buy” and a consensus target price of $81.55.

BridgeBio Pharma Trading Down 1.1%

BBIO opened at $75.25 on Friday. The stock has a market capitalization of $14.50 billion, a P/E ratio of -18.00 and a beta of 1.13. The stock has a 50-day moving average price of $75.60 and a 200-day moving average price of $63.08. BridgeBio Pharma has a 12-month low of $28.33 and a 12-month high of $84.94.

Insiders Place Their Bets

In other news, CAO Maricel Apuli sold 2,000 shares of the stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $74.26, for a total transaction of $148,520.00. Following the completion of the sale, the chief accounting officer directly owned 130,297 shares in the company, valued at approximately $9,675,855.22. This represents a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Neil Kumar sold 40,000 shares of the firm’s stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $71.94, for a total value of $2,877,600.00. Following the completion of the sale, the chief executive officer directly owned 695,686 shares in the company, valued at $50,047,650.84. The trade was a 5.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 300,700 shares of company stock worth $21,034,671. 18.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On BridgeBio Pharma

Several institutional investors and hedge funds have recently bought and sold shares of the business. Corient Private Wealth LLC purchased a new stake in shares of BridgeBio Pharma in the second quarter worth $643,000. WINTON GROUP Ltd purchased a new position in shares of BridgeBio Pharma in the 2nd quarter worth about $3,856,000. Principal Financial Group Inc. boosted its stake in BridgeBio Pharma by 23.0% in the 3rd quarter. Principal Financial Group Inc. now owns 1,267,412 shares of the company’s stock worth $65,829,000 after purchasing an additional 236,885 shares in the last quarter. Federated Hermes Inc. grew its position in BridgeBio Pharma by 53.0% during the 3rd quarter. Federated Hermes Inc. now owns 424,695 shares of the company’s stock valued at $22,059,000 after purchasing an additional 147,108 shares during the last quarter. Finally, Bosun Asset Management LLC increased its stake in BridgeBio Pharma by 119.7% during the 2nd quarter. Bosun Asset Management LLC now owns 26,154 shares of the company’s stock valued at $1,129,000 after purchasing an additional 14,250 shares in the last quarter. Hedge funds and other institutional investors own 99.85% of the company’s stock.

Key Headlines Impacting BridgeBio Pharma

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: PROPEL 3 Phase‑3 topline: infigratinib met the primary endpoint (annualized height velocity) with a meaningful treatment difference vs. placebo, reported favorable safety, and BridgeBio plans NDA/MAA submissions in H2 2026 — a major de‑risking and commercialization step that drove earlier buying interest. Read More.
• Positive Sentiment: Analyst upgrades/target bumps: Wells Fargo raised its target to $98 (overweight) and Oppenheimer lifted its target to $83 (outperform). Those upgrades reinforced the commercial/regulatory narrative and supported the rally earlier in the week. Read More. Read More.
• Positive Sentiment: Competitive impact: BridgeBio’s positive data pressured rival programs (reports note BioMarin and Ascendis shares fell), suggesting BridgeBio may gain market share if approvals follow. Read More.
• Neutral Sentiment: Short‑interest reporting shows zero shares (likely a data or reporting glitch) and is not informative for positioning; ignore that metric until corrected by exchanges/data vendors.
• Negative Sentiment: Insider selling: CEO Neil Kumar sold 40,000 shares on Feb 10 (~$2.88M), part of a pattern of recent sales. That can prompt profit‑taking or investor concern about insider conviction despite large remaining holdings. Read More.
• Negative Sentiment: Near‑term financials remain a risk: Zacks flagged likely negative earnings in the upcoming report, keeping short‑term P&L and cash‑burn concerns on the table despite the clinical win. Read More.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.